Paste composition, biodegradable injection paste and preparation method thereof
Through cross-linking and combined hydrogel technology, the problem of insufficient mechanical properties of hydrogel is solved, and microhydrogel particles with biocompatibility, adhesion and elastic balance are provided, realizing in medical and pharmaceutical applications Convenient and effective use.
Patent Information
- Application Number
- CN202380026841.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-11
- Filing Date
- 2023-03-07
- Publication Date
- 2024-11-26
AI Technical Summary
Existing hydrogels in medical and pharmacological applications are limited in parts that need to bear loads due to weak mechanical physical properties, especially low tensile strength, and are converted to provide a balance between viscosity and elasticity. When microgel particles are used, there are problems such as freezing, drying, crushing and rehydration.
Provided is a biodegradable paste composition for injection, a hydrogel formed by cross-linking, comprising an adhesive polymer having a single helical structure and a diglycidyl ether monomer, which is uniformly distributed in a carrier to form Supporting body skeleton, providing biocompatibility, adhesion and elastic balance of microhydrogel particles.
Achieves convenient application in the applicable area through a syringe without the need for mixing drug solutions, providing a balance between biocompatibility, adhesion, viscosity and elasticity, suitable for hemostatic agents, bone fillers, wound dressings, and drug carriers and other fields.
Smart Images

Figure CN119032122A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a paste composition, a biodegradable injection paste obtained therefrom and a preparation method thereof, and more particularly, to a paste composition, a biodegradable injection paste obtained therefrom and a preparation method thereof, wherein the paste composition uses a paste composition and a hydrogel formed by cross-linking as a paste phase, thereby providing the convenience of being applied to an applicable part using a single syringe, biocompatibility, adhesion, and viscoelastic balance. Background Art
[0002] Hydrogel is a three-dimensional structure composed of a network of hydrophilic molecules, most of which are composed of water. Hydrogel has high water content, porous structure and biocompatibility.
[0003] Hydrogels exhibit various properties depending on which polymer is used as the backbone or which cross-linking method is used.
[0004] When using synthetic compounds such as polyacrylic acid series polymers or polyvinylalcohol, the biocompatibility is low, but it is easy to chemically modify, so engineering applications are very easy. On the other hand, when natural compounds, especially collagen, fibrin and hyaluronic acid as extracellular matrix (ECM) components, are used as the main chain, they are not easy to deform and difficult to perform engineering operations, but because they are components derived from organisms, they have few side effects such as immune and inflammatory reactions during transplantation, and have the advantage of being suitable for clinical applications.
[0005] Hyaluronic acid has a structure represented by the following Chemical Formula 1, and may form a hydrogel having various physical properties through a covalent bond.
[0006] [Chemical formula 1]
[0007]
[0008] Gelatin is a natural polymer that has the triple-helix structure of collagen transformed into a single-helix form. Gelatin is classified into two forms, gelatin A and gelatin B, depending on the processing method. Gelatin A can be prepared by acid treatment, and gelatin B can be prepared by alkali treatment, so it can be prepared into two types.
[0009] Gelatin is widely used in tissue engineering due to its biocompatibility and easy processability. In particular, gelatin hydrogels can easily deliver growth factors and have many advantages in tissue regeneration. However, gelatin hydrogels also have the problem of weak mechanical strength.
[0010] As described above, hydrogels have a high water content and physical and chemical similarities with extracellular matrices and have high biocompatibility, and therefore various analyses are being conducted on the medical and pharmaceutical applications of hydrogels.
[0011] However, hydrogels have weak mechanical and physical properties, especially low tensile strength, so their application is limited in parts that need to bear loads, and ultimately there is a problem of undergoing an early dissolution process at the target site and disappearing in a short time.
[0012] As a related prior art document, Korean Patent Publication No. 2017-7032839 attempts to provide viscoelasticity while providing mechanical physical properties by PEGylated linear or branched multi-armed poly(ethylene glycol) (PEG) through multifunctional reactive groups.
[0013] However, in this case, in order to convert into microgel particles that can provide a balance between viscosity and elasticity, there is a problem that freezing, drying, pulverization and rehydration are required. Therefore, there is still a need to study and develop a biodegradable injection paste that is soluble and can provide a balance between biocompatibility, adhesion and viscoelasticity.
[0014] Furthermore, injectable hydrogels are cross-linked three-dimensional polymers and contain a considerable amount of water. Therefore, they have excellent biocompatibility and biodegradability and are widely used.
[0015] As an example, when used as a drug carrier, the injection hydrogel (dry powder type etc.) and the drug solution are mixed using 2 syringes and applied to a surgical site etc. Summary of the invention
[0016] 1. Technical issues to be resolved
[0017] The technical problem to be achieved by the present invention is to provide a paste composition which, by using a hydrogel formed by cross-linking, can provide the convenience of applying to an applicable place such as a surgical site using one syringe without mixing a drug solution, and a balance of biocompatibility, adhesion, and viscoelasticity.
[0018] Furthermore, the paste composition is used to provide a biodegradable paste for injection and a preparation method thereof.
[0019] The above-mentioned object and other objects of the present invention can be achieved by the present invention described below.
[0020] (II) Technical solution
[0021] In order to achieve the above-mentioned object, the present invention provides a biodegradable paste composition for injection, characterized in that it is a composition for controlled modification (water content adjustment) of a crosslinked product between a polymer and a monomer having a biodegradable unit, the composition comprising two or more backbone polymers, diglycidyl ether monomers, active ingredients or a mixture thereof; and a carrier, the two or more backbone polymers, diglycidyl ether monomers, active ingredients or a mixture thereof are uniformly distributed in the carrier, the backbone polymer or active ingredient comprises an adhesive polymer having a single-helix structure to form a support skeleton, and the carrier does not react with the backbone polymer, the diglycidyl ether monomer and the active ingredient.
[0022] The content of the carrier may be 80 wt % or more based on the total weight of the two or more backbone polymers, the adhesive polymer having a single helical structure, the diglycidyl ether monomer, the active ingredient and the carrier.
[0023] The adhesive polymer having a single helix structure can deform the triple-helix structure of collagen into a single helix form.
[0024] The adhesive polymer having a single helical structure may be a polymer that dissolves under alkaline conditions or a polymer that dissolves under acidic conditions.
[0025] When the adhesive polymer having a single helical structure includes the first backbone polymer among the two or more backbone polymers, the support backbone can be formed by bonding between the adhesive polymer having a single helical structure and the first backbone polymer.
[0026] When the adhesive polymer having a single helical structure is included in the active ingredient, the support skeleton can be formed by bonding between the first skeleton polymer and the second skeleton polymer.
[0027] The first backbone polymer may be a hyaluronic acid or natural polymer selected from hyaluronic acid, hyaluronate, collagen, gelatin, chitosan, starch, alginic acid and alginate.
[0028] The second backbone polymer may be a cellulosic or synthetic polymer selected from carboxymethyl cellulose, cellulose, polyvinyl pyrrolidone, poloxamer, polyvinyl alcohol and polyethylene glycol, except for the type repeated with the first backbone polymer.
[0029] The active ingredient contained in the first backbone polymer or the second backbone polymer can be one or more selected from starch, collagen, chitosan, carboxymethyl cellulose, sodium hyaluronate, polyvinyl pyrrolidone, poloxamer, polyethylene glycol, thrombin, fibrin, fibrinogen, tannic acid, vitamin K, bovine serum albumin (BSA), gentamicin, hemostatic agent, calcium chloride, drug carrier, wound dressing, skin soothing, moisturizing, anti-inflammatory, atopic dermatitis, and natural active ingredients, excluding the types repeated with the first backbone polymer or the second backbone polymer.
[0030] The carrier can be provided in phosphate buffered saline, purified water, water for injection or physiological saline.
[0031] Among the components constituting the paste composition, the weight ratio of the adhesive polymer having a single helical structure: two or more backbone polymers (total amount of two or more): diglycidyl ether monomer: carrier: active ingredient can be 0.1 to 15: 0.05 to 7: 0.00001 to 5: 82 to 95: 0 to 0.9.
[0032] In addition, the present invention provides a biodegradable injection paste, characterized in that the biodegradable injection paste is obtained from the above-mentioned paste composition, the biodegradable injection paste contains two or more backbone polymers, diglycidyl ether monomers, active ingredients and carriers, an adhesive polymer having a single helical structure is contained in the backbone polymer or the active ingredient to provide a micro-hydrogel particle form that maintains viscoelastic balance, based on the total weight of the backbone polymer, diglycidyl ether monomers, active ingredients and carriers, containing 80% by weight or more of the carrier, and presenting a paste form that can be applied to an applicable area using a single syringe.
[0033] The size of the micro hydrogel particles may be 100 μm to 600 μm.
[0034] The biodegradable injection paste can be an undried powder with an average particle size of 50 μm to 400 μm. The undried powder with a capacity of 1 ml to 7 ml is filled in an injection container with a volume of 10 ml, and the thrust (injection force or extrusion force) measured by a universal tensile testing machine can be 40 N or less, preferably 30 N or less.
[0035] The biodegradable paste for injection is an adhesive polymer powder, and the adhesive force measured by a rheometer and an adhesive force test may be 5N or more, preferably 9N or more.
[0036] In addition, after applying 10 ml of water to 0.2 g of the sample, the absorption capacity was confirmed by measuring the weight after a predetermined time at 37°C and 50 rpm. The water content measured by a moisture meter was 80 to 95%.
[0037] In addition to measuring the water absorption of the biodegradable paste for injection, whether blood is absorbed and the time are also measured. An appropriate amount of blood is dripped into the test body, and the blood is turned 180 degrees every 10 seconds to measure whether blood is absorbed and the time. Afterwards, according to the blood coagulation index confirmation test method, after measuring with an ELISA instrument, the blood coagulation index (BCI) calculated according to the following mathematical formula 1 can be 70% or more, preferably 74% or more.
[0038] [Mathematical formula 1]
[0039] BCI(%)=100-((D o / D s )×100)
[0040] (Among them, D s Refers to the absorbance of hemoglobin solution, D o It refers to the absorbance of hemolyzed whole blood. BCI value refers to the blood coagulation rate, and a high BCI value indicates better coagulation performance.
[0041] The biodegradable paste for injection may have a complex viscosity of 3,000,000 cP or more, preferably 10,000,000 cP or more, as measured at 0.1 Hz using a rheometer with a P25 spindle and a 0.5 g sample.
[0042] The biodegradable paste for injection is subjected to in vitro ( in vitro ) Decomposition test was carried out in a shaking incubator at 37°C and 100 rpm for different time periods to confirm the degree of decomposition. It was confirmed that almost all the decomposition was achieved after 48 hours.
[0043] In addition, the present invention provides a method for preparing a biodegradable injection paste, characterized in that the preparation method comprises: a first step of preparing a first skeleton polymer and adding it to an alkaline substance to prepare a base preparation; a second step of adding the base preparation to a diglycidyl ether monomer and cross-linking it to prepare a porous support; and a third step of purifying and crushing the porous support to obtain a biodegradable injection paste and binding an active ingredient on its surface, wherein the base preparation or the biodegradable injection paste contains an adhesive polymer with a single helical structure that can be dissolved under alkaline conditions, and the biodegradable injection paste is provided in the form of a wet paste through a carrier provided during purification.
[0044] The alkaline substance used in the first step may be 0.1N to 1N hydroxide of sodium, potassium or calcium, preferably 0.1N to 0.5N sodium hydroxide.
[0045] Preferably, the active ingredient contained in the first backbone polymer or the second backbone polymer is one or more selected from starch, collagen, chitosan, carboxymethyl cellulose, sodium hyaluronate, polyvinyl pyrrolidone, poloxamer, polyethylene glycol, thrombin, fibrinogen, tannic acid, vitamin K, bovine serum albumin (BSA), gentamicin, hemostatic agent, calcium chloride, drug carrier, wound dressing, skin soothing, moisturizing, anti-inflammatory, atopic dermatitis, and natural active ingredients, excluding the types repeated with the above-mentioned first backbone polymer or second backbone polymer.
[0046] Preferably, the carrier is provided in phosphate buffered saline, purified water, water for injection or physiological saline.
[0047] Preferably, two or more backbone polymers, diglycidyl ether monomers, active ingredients or mixtures thereof are uniformly distributed in the carrier, the backbone polymer or active ingredient comprises an adhesive polymer having a single helical structure to form a support skeleton, and the carrier does not react with the backbone polymer, the diglycidyl ether monomer and the active ingredient.
[0048] Preferably, among the components constituting the biodegradable paste composition, the weight ratio of an adhesive polymer having a single helical structure: two or more backbone polymers (the total amount of two or more): a diglycidyl ether monomer: a carrier: an active ingredient is 0.1 to 15: 0.05 to 7: 0.00001 to 5: 82 to 95: 0 to 0.9.
[0049] Preferably, based on the total weight of the two or more backbone polymers, the adhesive polymer having a single helical structure, the diglycidyl ether monomer, the active ingredient and the carrier, the content of the carrier may be 80% by weight or more.
[0050] Preferably, the adhesive polymer having a single helical structure can deform the triple helical structure of collagen into a single helical form.
[0051] Preferably, when the adhesive polymer having a single helical structure includes a first backbone polymer among the two or more backbone polymers, the support backbone is formed by bonding between the adhesive polymer having a single helical structure and the first backbone polymer.
[0052] Preferably, when the adhesive polymer having a single helical structure is contained in the active ingredient, the support skeleton is formed by bonding between the first skeleton polymer and the second skeleton polymer.
[0053] In the third step, the purification can be repeated up to 9 times using a carrier of phosphate buffered saline, purified water, water for injection or saline, and the residual cross-linking agent can be removed from the porous support while being neutralized, and then pulverized into an average particle size in the range of 50 μm to 500 μm.
[0054] (III) Beneficial effects
[0055] The biodegradable paste for injection obtained from the paste composition according to the present invention is soluble, and has the effect of providing a balance between biocompatibility, adhesive force, viscosity and elasticity.
[0056] In particular, the biodegradable paste for injection according to the present invention provides soluble wettable powder in a state uniformly distributed in a carrier, and thus can be used in the fields of hemostatic agents, bone fillers, wound dressings, drug carriers, tissue repair materials, skin soothing, moisturizing, anti-inflammatory, atopic dermatitis therapeutic agents, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Figure 1 The graphs show the properties of the product of Example 1 according to the present invention, and the microscope photograph on the right is a graph with a radius of 1 mm. The black dots in the microscope photograph on the right represent bubbles.
[0058] Figure 2 This is a product photograph showing a blood absorption test of the product according to Example 1 of the present invention. Similarly, the microscope photograph on the right is a diagram with a radius of 1 mm. As shown in the microscope photograph on the right, it can be confirmed that the blood is well absorbed between the pastes.
[0059] Figure 3 : is a scanning electron microscope (SEM) photograph showing the dried product according to Example 1 of the present invention. As shown in the photograph, porous beads can be confirmed. DETAILED DESCRIPTION
[0060] Hereinafter, the paste composition, the biodegradable paste for injection and the method for producing the same of the present invention will be described in detail.
[0061] The present inventors have studied a biodegradable paste for injection which can be applied using one syringe without mixing a drug solution using two syringes and is applicable to a surgical site, etc., and which has a balance between solubility, biocompatibility, adhesion, viscosity and elasticity. The present inventors have confirmed that the above-mentioned objects can be achieved when a paste composition provided in the form of a wet paste is used, wherein the wet paste comprises an undried powder in which a natural polymer having a specific structure is incorporated in the skeleton or on the surface and purified by cross-linking with a specified cross-linking agent. Based on this diligent study, the present invention has been completed.
[0062] Paste composition
[0063] In one embodiment of the present invention, the paste composition refers to a composition for controlled modification (water content adjustment) of a polymer having a biodegradable unit and a crosslinker between monomers.
[0064] The paste composition comprises two or more backbone polymers, diglycidyl ether monomers, active ingredients or mixtures thereof; and a carrier, wherein the two or more backbone polymers, diglycidyl ether monomers, active ingredients or mixtures thereof are uniformly distributed in the carrier, and the backbone polymer or active ingredient comprises an adhesive polymer having a single helical structure to form a support skeleton.
[0065] The carrier is characterized in that it does not react with the backbone polymer, the diglycidyl ether monomer, and the active ingredient. In this case, a biodegradable injectable paste can be provided that can be applied using one syringe without using two syringes to mix the drug solution and apply it to the surgical site, etc., and has solubility and a balance between biocompatibility, adhesion, viscosity and elasticity.
[0066] In one embodiment of the present invention, the pasty composition includes wettability as one of the greatest characteristics.
[0067] Unless otherwise specifically defined, the term "wetness" refers to a state of containing excessive moisture such that the moisture content measured using a moisture meter is 80% or more.
[0068] In order to achieve the above-mentioned wettability, in one embodiment of the present invention, based on the total weight of the two or more backbone polymers, the adhesive polymer having a single helical structure, the diglycidyl ether monomer, the active ingredient and the carrier, the content of the carrier can be more than 80 weight %. As a specific example, it can be in the range of 82 weight to 95 weight. Within this range, it contains too much water without shortening the decomposition rate, so it can remain stable before application.
[0069] The adhesive polymer having a single helical structure may be a triple helical structure of collagen deformed into a single helical form.
[0070] As the adhesive polymer having a single helical structure, a polymer that dissolves under acidic conditions may be used, but a polymer that dissolves under alkaline conditions is preferably used because it facilitates the control of the reaction.
[0071] When the adhesive polymer having a single helical structure includes the first backbone polymer among the two or more backbone polymers, the support backbone can be formed by bonding between the adhesive polymer having a single helical structure and the first backbone polymer.
[0072] When the adhesive polymer having a single helical structure is included in the active ingredient, the support skeleton can be formed by bonding between the first skeleton polymer and the second skeleton polymer.
[0073] The first backbone polymer may be a hyaluronic acid or natural polymer selected from hyaluronic acid, hyaluronate, collagen, gelatin, chitosan, starch, alginic acid and alginate.
[0074] The second backbone polymer may be a cellulosic or synthetic polymer selected from carboxymethyl cellulose, cellulose, polyvinyl pyrrolidone, poloxamer, polyvinyl alcohol and polyethylene glycol, excluding the type repeated with the first backbone polymer.
[0075] The diglycidyl ether monomer is not limited thereto, but may be an alkanediol diglycidyl ether having a carbon number of 1 to 8. In this case, cross-linking between the backbone polymers may be effectively performed without reducing the mechanical physical properties of the backbone polymers.
[0076] As an example, the active ingredient can be one or more selected from starch, collagen, chitosan, carboxymethyl cellulose, sodium hyaluronate, polyvinyl pyrrolidone, poloxamer, polyethylene glycol, thrombin, fibrinogen, tannic acid, vitamin K, bovine serum albumin (BSA), gentamicin, hemostatic agent, calcium chloride, drug carrier, wound dressing, skin soothing, moisturizing, anti-inflammatory, atopic dermatitis, and natural active ingredients.
[0077] The carrier can be provided in phosphate-buffered saline, purified water, water for injection or saline. As described above, as an example, based on the total content of the backbone polymer, diglycidyl ether monomer, active ingredient and water, the content of the carrier is 80% by weight or more. As a specific example, when the content of the carrier is in the range of 82% by weight to 95% by weight, it exhibits excessive wettability and is therefore preferred.
[0078] Among the components constituting the biodegradable injection paste, as an example, when the weight ratio of the adhesive polymer having a single helical structure: the backbone polymer (when the adhesive polymer having a single helical structure is included in the backbone polymer, the polymer other than this): the diglycidyl ether monomer: water: the active ingredient is 0.1 to 15: 0.05 to 7: 0.00001 to 5: 82 to 95: 0 to 0.9, it has the effect of being soluble while having an excellent balance between biocompatibility, adhesive force, viscosity and elasticity.
[0079] Among the components constituting the paste composition, as an example, when the weight ratio of an adhesive polymer having a single helical structure: two or more backbone polymers: a diglycidyl ether monomer: water: an active ingredient is 0.1 to 15: 0.05 to 7: 0.00001 to 5: 82 to 95: 0 to 0.9, as a specific example, when the weight ratio is 0.15 to 14: 0.3 to 6.6: 0.00001 to 5: 84 to 93: 0.1 to 0.35, it has the effect of being soluble while having a better balance between biocompatibility, adhesion, viscosity and elasticity.
[0080] <Biodegradable paste for injection>
[0081] In one embodiment of the present invention, the biodegradable injection paste is preferably obtained from a paste composition for controlled modification (water content adjustment) of a polymer having the biodegradable unit and a crosslinker between monomers.
[0082] As an example, the biodegradable paste for injection is characterized in that it contains two or more backbone polymers, diglycidyl ether monomers, active ingredients and carriers, and an adhesive polymer having a single helical structure is contained in the backbone polymer or the active ingredient to provide a micro-hydrogel particle form that maintains a viscoelastic balance. The total weight of the backbone polymer, diglycidyl ether monomer, active ingredient and carrier is used as a basis, and the carrier is contained in an amount of 80% by weight or more, presenting a paste form that can be applied to an applicable part using a single syringe. In this case, it has the effect of being soluble while having excellent biocompatibility, adhesive force, and a balance between viscosity and elasticity.
[0083] As an example, the size of the micro hydrogel particles may be 100 μm to 600 μm, and as a specific example, may be 200 μm to 400 μm, in which case, the best and greatest effect on the water absorption rate may be provided.
[0084] The biodegradable paste for injection is characterized in that it is an undried powder with an average particle size of 50 μm to 400 μm, as a specific example, an average particle size of 100 μm to 400 μm, and as a preferred example, an average particle size of 200 μm to 400 μm, in order to provide excessive wettability, so the drying process is omitted.
[0085] When the average particle size is such, the preparation is easy and the blood absorption capacity is excellent. The average particle size can be measured by SEM image analysis.
[0086] The syringe thrust (injection force or elastic force) of the biodegradable injection paste can be 5 times or less of the adhesive force, and as a specific example, can be in the range of 1 to 4 times. In this case, it has the effect of excellent usability, easy adhesion to the application site, and improved efficacy.
[0087] The injection force can be measured using an injection container having a volume of 10 ml and utilizing a universal tensile testing machine.
[0088] The adhesion can be measured using a rheometer.
[0089] The biodegradable injection paste is dripped with blood into a test body, and after being placed for a period of time a, it is flipped 180 degrees to measure whether the blood is absorbed and the time. 1) According to a moisture absorption test, the paste absorbs moisture to measure the amount of moisture absorption. According to a blood coagulation index confirmation test method, after measurement using an ELISA instrument, the blood coagulation index (BCI) calculated according to the following mathematical formula 1 can be greater than 70%, preferably greater than 74%.
[0090] [Mathematical formula 1]
[0091] BCI(%)=100-((D o / D s )×100)
[0092] (Among them, D s Refers to the absorbance of hemoglobin solution, D o It refers to the absorbance of hemolyzed whole blood. BCI value refers to the blood coagulation rate, and a high BCI value indicates better coagulation performance. AAfter applying 0.2 ml of blood to 0.2 g of the test body, turn it 180 degrees every 10 seconds, and measure the time it takes for all the blood to be absorbed and drip. Water absorption capacity is confirmed by applying 10 ml of water to 0.2 g of the test body, measuring the weight after 24 hours at 37°C and 50 rpm. )
[0093] Preferably, the water content of the biodegradable injection paste measured by a moisture meter can be 80% or more, and as a specific example, it can be 80% to 95%. In this case, one syringe can be used to directly provide it to an applicable site such as a surgical site without using two syringes to mix the drug solution.
[0094] The biodegradable paste for injection may have a complex viscosity of 3,000,000 cP or more, preferably 9,000,000 cP or more, as measured at 0.1 Hz using a rheometer with a P25 spindle and a 0.5 g sample.
[0095] The cell viability of the biodegradable paste for injection measured according to ISO 10993-cytotoxicity measurement method may be 80% or more, and preferably 89% or more.
[0096] The biodegradable paste for injection has an effect of no detection of bacteria according to the results of measurement by the Korean Pharmacopoeia Sterility Test Method.
[0097] According to the results measured by the cytotoxicity test method, the biodegradable paste for injection has a non-cytotoxic effect.
[0098] As a result of confirming the residual amount of the cross-linking agent by an internal standard method using a GC chromatograph, the biodegradable paste for injection has an effect of having a residual amount of the cross-linking agent of 1% by weight or less.
[0099] <Method for preparing biodegradable injection paste>
[0100] The method for preparing a biodegradable paste for injection according to a specific embodiment of the present invention includes a first step of preparing a base preparation, a second step of preparing a support, and a third step of obtaining the biodegradable paste for injection.
[0101] Specifically, in the first step, a first backbone polymer may be prepared and added to a basic substance to prepare a matrix preparation.
[0102] The first backbone polymer may include an adhesive polymer having a single helical structure that can be dissolved under alkaline conditions. In this case, a paste containing appropriate water content may be prepared, thereby providing a continuous form-maintaining effect.
[0103] When the backbone polymer includes an adhesive polymer having a single helical structure that can be dissolved under alkaline conditions, the additional polymer equivalent to the remaining backbone polymer can be a hyaluronic acid or natural polymer selected from hyaluronic acid, hyaluronate, collagen, gelatin, chitosan, starch, alginic acid and alginate. In this case, a synergistic effect between the extrusion force and the adhesive force can be provided.
[0104] When the first backbone polymer does not include an adhesive polymer having a single helical structure that can be dissolved under alkaline conditions, the two or more backbone polymers may include the first backbone polymer and a second backbone polymer different therefrom. The second backbone polymer may be a cellulose or synthetic polymer selected from carboxymethyl cellulose, cellulose, polyvinyl pyrrolidone, poloxamer, polyvinyl alcohol and polyethylene glycol, except for the type repeated with the first backbone polymer.
[0105] Furthermore, the first backbone polymer and the second backbone polymer may contain active ingredients as needed. The active ingredient may be selected from starch, collagen, chitosan, carboxymethyl cellulose, sodium hyaluronate, polyvinyl pyrrolidone, poloxamer, polyethylene glycol, thrombin, fibrin, fibrinogen, tannic acid, vitamin K, bovine serum albumin (BSA), gentamicin, hemostatic agent, calcium chloride, drug carrier, wound dressing, skin soothing, moisturizing, anti-inflammatory, atopic dermatitis, natural active ingredients in one or more, and with the first backbone polymer or the second backbone polymer repeating species except.
[0106] The alkaline substance used in the first step may contain an alkali metal such as sodium, potassium or calcium at 0.1 N to 0.5 N. In this case, the solubility of the base preparation can be improved, which is preferred.
[0107] In the second step, the matrix preparation may be added to a diglycidyl ether monomer for cross-linking, thereby preparing a porous support.
[0108] In the third step, the porous support may be purified and crushed to obtain a biodegradable paste for injection, and an active ingredient may be bound to the surface of the biodegradable paste.
[0109] The biodegradable paste for injection may contain an adhesive polymer having a single helical structure that can be dissolved under alkaline conditions.
[0110] In the third step, purification can be performed using phosphate buffered saline, purified water, water for injection or saline, and the purification can be repeated up to 9 times to remove residual cross-linking agent from the porous support while neutralizing it, and then it can be crushed into an average particle size in the range of 50μm to 500μm.
[0111] The water provided during the purification can be provided in the form of a wet paste.
[0112] In particular, when the biodegradable paste for injection of the present invention is used as a hemostatic agent, the hemostatic ability is improved together with the active ingredient, thereby being able to exhibit excellent performance as a hemostatic agent.
[0113] In particular, when the biodegradable paste for injection of the present invention is used as a bone filler, physical properties are improved together with the active ingredient, thereby being able to exhibit excellent performance as a bone filler.
[0114] That is, the biodegradable paste for injection according to an embodiment of the present invention is provided in a state uniformly distributed in a carrier, and is thus suitable for use in the fields of hemostatic agents, bone fillers, wound dressings, drug carriers, tissue repair materials, skin soothing, moisturizing, anti-inflammatory, atopic dermatitis therapeutic agents, and the like.
[0115] In order to help understand the present invention, preferred embodiments are proposed below. However, the following embodiments are merely illustrative of the present invention. Various changes and modifications can be made within the scope of the present invention and the technical concept. This is obvious to those skilled in the art, and it is reasonable that such variations and modifications fall within the scope of rights.
[0116] [Example: Preparation of biodegradable injection paste]
[0117] Example 1
[0118] As a paste composition used in Example 1, gelatin and sodium hyaluronate were prepared.
[0119] Specifically, 30 wt % of the gelatin and 0.84 wt % of sodium hyaluronate were mixed and dissolved in 0.25 N NaOH.
[0120] 0.84 wt % of 1,4-butanediol diglycidyl ether was added to the above-mentioned dissolved material, and the mixture was cross-linked at 30° C. for 18 hours to prepare a support main chain.
[0121] The crosslinked product was purified repeatedly 8-9 times using phosphate buffered saline to remove residual butanediol diglycidyl ether and neutralize the pH.
[0122] The obtained biodegradable injection paste consists of 13.64 wt % of gelatin, 0.38 wt % of sodium hyaluronate, 0.0002 wt % of 1,4-butanediol diglycidyl ether, and 85.84 wt % of phosphate buffered saline.
[0123] The phosphate buffered saline used at this time was a solution composed of 84.87% by weight of purified water, 0.71% by weight of sodium chloride, 0.04% by weight of potassium dihydrogen phosphate, and 0.22% by weight of disodium hydrogen phosphate dodecahydrate.
[0124] Next, the granules were pulverized using a plunge mill until the average particle size became 300 μm.
[0125] Thereafter, 0.14% by weight of calcium chloride dihydrate was mixed with the ground product to prepare a biodegradable paste for injection in the form of a paste having an active ingredient bound to the surface.
[0126] Example 2
[0127] As a paste composition used in Example 1, sodium hyaluronate and carboxymethylcellulose were prepared.
[0128] Specifically, 15.24 wt % of sodium hyaluronate and 7.62 wt % of carboxymethyl cellulose were mixed and dissolved in 25N NaOH.
[0129] 0.95 wt % of 1,4-butanediol diglycidyl ether was added to the above-mentioned dissolved material, and the mixture was cross-linked at 30° C. for 18 hours to prepare a support main chain.
[0130] The crosslinked product was purified repeatedly 8-9 times using phosphate buffered saline to remove residual butanediol diglycidyl ether and neutralize the pH.
[0131] The biodegradable injection paste prepared after purification was composed of 4.32 wt % of sodium hyaluronate, 2.16 wt % of carboxymethyl cellulose, 0.0002 wt % of 1,4-butanediol diglycidyl ether, and 93.18 wt % of phosphate buffered saline.
[0132] Next, the granules were pulverized using a plunge mill until the average particle size became 300 μm.
[0133] Thereafter, 0.14% by weight of calcium chloride dihydrate and 0.2% by weight of gelatin were mixed with the ground product to prepare a biodegradable paste for injection in the form of a paste having an active ingredient bound to the surface.
[0134] Example 3
[0135] The same process as in Example 1 was repeated, except that in Example 1, gelatin in an amount equivalent to that of calcium chloride dihydrate was further used and calcium chloride dihydrate was not included, thereby preparing a biodegradable injection paste in a paste form.
[0136] Example 4
[0137] The same process as in Example 2 was repeated, except that in Example 2, gelatin in an amount equivalent to that of calcium chloride dihydrate was further used and calcium chloride dihydrate was not included, thereby preparing a biodegradable paste for injection in a paste form.
[0138] Comparative Example 1
[0139] The same process as in Example 1 was repeated, except that in Example 1, sodium hyaluronate in an amount equivalent to that of gelatin was also used and gelatin was not included, thereby attempting to prepare a biodegradable injection paste in the form of a paste, but the paste could not be prepared in the shape of beads.
[0140] Comparative Example 2
[0141] The same process as in Example 1 was repeated except that, in Example 1, gelatin in an amount equivalent to that of sodium hyaluronate was further used and sodium hyaluronate was not included, thereby preparing a biodegradable paste for injection in a paste form.
[0142] Comparative Example 3
[0143] The same process as in Example 1 was repeated, except that in Example 1, 10 wt % of gelatin was mixed and used to prepare a biodegradable paste for injection in the form of a paste.
[0144] Comparative Example 4
[0145] The same process as in Example 2 was repeated, except that in Example 2, only carboxymethyl cellulose was used and sodium hyaluronate was excluded, thereby preparing a biodegradable injection paste in a paste form.
[0146] Comparative Example 5
[0147] The same process as in Example 1 was repeated, except that in Example 1, polyethylene glycol diacrylate (PEGDA) was used instead of 1,4-butanediol diglycidyl ether to prepare a hyaluronic acid cross-linked body in a paste form.
[0148] Comparative Example 6
[0149] The same process as in Example 1 was repeated, except that in Example 1, the product was pulverized after purification and then freeze-dried to prepare a biodegradable paste for injection in the form of a paste.
[0150] Reference Example 1
[0151] The same process as in Example 1 was repeated except that the pulverization size of 300 μm in Example 1 was changed to 700 μm, thereby preparing a biodegradable paste for injection in the form of a paste.
[0152] Reference Example 2
[0153] The same process as in Example 1 was repeated, except that in Example 1, the pulverization size of 300 μm was changed to 30 μm to prepare a biodegradable injection paste in the form of a paste. However, since the pulverization mesh size of the pulverization equipment was too small, the test body could not be manufactured.
[0154] Test example
[0155] For Examples 1 to 4, Comparative Examples 2 to 6, and Reference Example 1 prepared above, the complex viscosity (complex viscosity), adhesion, injection force, hemostatic performance (blood absorption capacity), blood coagulation index (BCI), cytotoxicity, and sterility test were measured as follows, and the measurement results are shown in Table 1 below.
[0156] <Physical properties measurement method>
[0157] *Complex viscosity: The complex viscosity at 0.1 Hz was measured using a rheometer with a P25 spindle and a 0.5 g sample according to the complex viscosity measurement method.
[0158] * Adhesion: Based on the Tack test method, using a rheometer with a P25 spindle and a 0.5g test body, the maximum force is measured when the test liquid is pressed with a specified force (1N) and then lifted at a speed of 1.25mm / min.
[0159] *Injection force: Based on the Injectability test, measured using a universal material testing machine at a speed of 1 mm / s.
[0160] *Hemostasis performance (blood absorption capacity): Drop blood into the test object. When the test object drips directly, it is marked as 0 seconds. When it does not drop, turn it 180 degrees every 10 seconds to check whether it drops or not, until 60 seconds.
[0161] *Blood coagulation index (BCI): measured using an enzyme-labeled instrument based on the blood coagulation index confirmation test method.
[0162] *Cytotoxicity: Measured according to the cytotoxicity assay, cell viability is expressed as %.
[0163] *Sterility test: Confirm whether bacteria are detected according to the sterility test method, and mark it as yes or no.
[0164] * Moisture content: Use a moisture meter to measure the moisture content of the test piece.
[0165] Table 1
[0166]
[0167] As shown in Table 1, in Examples 1 to 4 of the biodegradable paste for injection of the present invention, appropriate ranges are provided for all measurement items of complex viscosity, adhesive force, injection force, blood absorption capacity, blood coagulation index (BCI), cytotoxicity, sterility test and water content, thereby providing an effect of providing a balance between biocompatibility, adhesive force, viscosity and elasticity while having solubility.
[0168] On the other hand, in the case of Comparative Examples 1 to 6, which are biodegradable pastes for injection that do not belong to the present invention, it was confirmed that they could not be prepared, or even if they could be prepared, the adhesive force, absorption force, extrusion force, etc. were not suitable.
[0169] Specifically, in the case of Comparative Example 1 in which the first skeleton polymer was used in an amount corresponding to the content of the adhesive polymer and no adhesive polymer was used, the adhesive bonding performance was insufficient and a paste could not be prepared.
[0170] In addition, in the case of Comparative Example 2 in which the adhesive polymer was used in an amount corresponding to the content of the first skeleton polymer, a decrease in adhesive force was confirmed.
[0171] In addition, in Comparative Example 3 in which the adhesive polymer was added in an excessive amount and in Comparative Example 4 in which the second skeleton polymer was used alone, it was confirmed that the absorption capacity was decreased.
[0172] Furthermore, in the case of Comparative Example 5 in which polyethylene glycol diacrylate was used as a cross-linking agent, different from the cross-linking agent used above, it was confirmed that the cytotoxicity was high.
[0173] In the case of Comparative Example 6 in which the obtained paste form was processed into a dry powder type, it was confirmed that the pressing force was relatively high, resulting in poor processability.
[0174] Furthermore, when the obtained paste was pulverized into an excessively large size, as shown in Reference Example 1, the absorption capacity was poor, and when it was pulverized into an excessively small size, as seen from Reference Example 2, it could not be prepared.
[0175] Therefore, when the biodegradable injection paste of the present invention is provided in the form of a wet paste in which an undried powder containing a natural polymer having a specific structure is contained in the skeleton or on the surface and purified by cross-linking with a specified cross-linking agent, the biodegradable injection paste can be provided in a state where the biodegradable injection paste is uniformly distributed in a carrier, thereby being suitable for use in the fields of hemostatic agents, bone fillers, wound dressings, drug carriers, tissue repair materials, skin soothing, moisturizing, anti-inflammatory, atopic dermatitis therapeutic agents, etc.
Claims
1. A paste composition, characterized in that: The paste composition is a composition for controlled modification, i.e., water content adjustment of a polymer having a biodegradable unit and a crosslinked product between a monomer, The composition comprises two or more backbone polymers, a diglycidyl ether monomer, an active ingredient or a mixture thereof; and a carrier, The two or more backbone polymers, diglycidyl ether monomers, active ingredients or mixtures thereof are uniformly distributed in the carrier, the backbone polymer or active ingredient comprises an adhesive polymer having a single helical structure to form a support skeleton, and the carrier does not react with the backbone polymer, the diglycidyl ether monomer and the active ingredient.
2. The paste composition according to claim 1, characterized in that The content of the carrier is 80% by weight or more based on the total weight of the two or more backbone polymers, the adhesive polymer having a single helical structure, the diglycidyl ether monomer, the active ingredient and the carrier.
3. The paste composition according to claim 1, characterized in that The adhesive polymer having a single helical structure deforms the triple helical structure of collagen into a single helical form.
4. The paste composition according to claim 1, characterized in that When the adhesive polymer having a single helical structure includes the first backbone polymer among the two or more backbone polymers, the support backbone is formed by bonding between the adhesive polymer having a single helical structure and the first backbone polymer.
5. The paste composition according to claim 1, characterized in that When the adhesive polymer having a single helical structure is contained in the active ingredient, the support skeleton is formed by bonding between the first skeleton polymer and the second skeleton polymer.
6. The paste composition according to claim 1, characterized in that The first backbone polymer is a hyaluronic acid or natural polymer selected from hyaluronic acid, hyaluronate, collagen, gelatin, chitosan, starch, alginic acid and alginate.
7. The paste composition according to claim 1, characterized in that The second backbone polymer is a cellulosic or synthetic polymer selected from carboxymethyl cellulose, cellulose, polyvinyl pyrrolidone, poloxamer, polyvinyl alcohol and polyethylene glycol, except for the type repeated with the first backbone polymer.
8. The paste composition according to claim 1, characterized in that The active ingredient is one or more selected from starch, collagen, chitosan, carboxymethyl cellulose, sodium hyaluronate, polyvinyl pyrrolidone, poloxamer, polyethylene glycol, thrombin, fibrinogen, tannic acid, vitamin K, bovine serum albumin (BSA), gentamicin, hemostatic agent, calcium chloride, drug carrier, wound dressing, skin soothing, moisturizing, anti-inflammatory, atopic dermatitis, and natural active ingredients, excluding those that are repeated with the first backbone polymer or the second backbone polymer.
9. The paste composition according to claim 1, characterized in that The carrier is provided in the form of phosphate buffered saline, purified water, water for injection or saline.
10. The paste composition according to claim 1, characterized in that Among the components constituting the paste composition, the weight ratio of the adhesive polymer having a single helical structure: the total amount of two or more types of backbone polymers: the diglycidyl ether monomer: the carrier: the active ingredient is 0.1 to 15: 0.05 to 7: 0.00001 to 5: 82 to 95: 0 to 0.
9.
11. A biodegradable paste for injection, characterized in that: The biodegradable paste for injection is obtained from the paste composition according to any one of claims 1 to 10, The biodegradable paste for injection comprises two or more backbone polymers, a diglycidyl ether monomer, an active ingredient and a carrier. The adhesive polymer having a single helical structure is contained in the backbone polymer or the active ingredient to provide a micro-hydrogel particle form that maintains viscoelastic balance, and the total weight of the backbone polymer, diglycidyl ether monomer, active ingredient and carrier is used as the basis, and the carrier is contained in an amount of 80% by weight or more, and the paste form can be applied to the applicable area using a single syringe.
12. The biodegradable paste for injection according to claim 11, characterized in that: The size of the micro hydrogel particles is 100 μm to 600 μm.
13. The biodegradable paste for injection according to claim 11, characterized in that: The biodegradable injection paste is an undried powder with an average particle size of 50 μm to 400 μm. The undried powder is filled in a 10 ml injection container with a capacity of 1 ml to 7 ml, and the thrust, i.e., injection force or extrusion force measured by a universal tensile testing machine is 40 N or less.
14. The biodegradable paste for injection according to claim 11, characterized in that: The biodegradable paste for injection contains an adhesive polymer powder having an adhesive force of 5 N or more as measured by an adhesive force test using a rheometer.
15. The biodegradable paste for injection according to claim 11, characterized in that: After adding 10 ml of water to 0.2 g of the test body, the biodegradable paste for injection had a water content of 80% to 95% when measured by a moisture meter at 37° C. and 50 rpm.
16. The biodegradable paste for injection according to claim 11, characterized in that: The blood coagulation index (BCI) of the biodegradable paste for injection is 70% or more. The blood coagulation index (BCI) is calculated by dropping an appropriate amount of blood into a test body, turning the test body 180 degrees every 10 seconds, and measuring whether the blood is absorbed and the time. After measuring with an ELISA instrument according to the blood coagulation index confirmation test method, the following mathematical formula 1 is used: [Mathematical formula 1] BCI(%)=100-((D o / D s )×100) Among them, D s Refers to the absorbance of hemoglobin solution, D o It refers to the absorbance of hemolyzed whole blood. The BCI value refers to the blood coagulation rate. A high BCI value indicates better coagulation performance.
17. The biodegradable paste for injection according to claim 11, characterized in that: The biodegradable paste for injection has a complex viscosity of 3,000,000 cP or more when measured at 0.1 Hz using a rheometer with a P25 spindle and a 0.5 g sample.
18. A method for preparing a biodegradable paste for injection, characterized in that: The preparation method comprises: In the first step, a first backbone polymer is prepared and added to an alkaline substance to prepare a matrix preparation; The second step is to add the matrix preparation to the diglycidyl ether monomer and cross-link it with the second backbone polymer to prepare a porous support; and The third step is to obtain a biodegradable paste for injection by purifying and crushing the porous support, and to bind the active ingredient on the surface of the porous support. wherein the base preparation or the biodegradable paste for injection contains an adhesive polymer having a single helical structure that can be dissolved under alkaline conditions, The biodegradable injection paste is provided in the form of a wet paste by means of a carrier provided during purification.
Citation Information
Cited By
Rhodomonas mucilaginosa-sourced extracellular vesicles as well as hydrogel composition and application thereof
CN120424834A
